Oncolytics Biotech, Inc. (TSE:ONC) shares were up 15.8% on Monday . The company traded as high as C$1.69 and last traded at C$1.69, approximately 107,929 shares were traded during trading. An increase of 85% from the average daily volume of 58,482 shares. The stock had previously closed at C$1.46.
Separately, Roth Capital restated a “buy” rating on shares of Oncolytics Biotech in a research report on Wednesday, September 4th.
The company has a debt-to-equity ratio of 17.51, a quick ratio of 3.02 and a current ratio of 3.78. The business has a fifty day simple moving average of C$1.21 and a 200 day simple moving average of C$1.50. The stock has a market cap of $45.07 million and a price-to-earnings ratio of -1.81.
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Further Reading: Most Active Stocks
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.